Cisplatin (Platinol ®)
Targeting YB-1 via entinostat enhances cisplatin sensitivity of pleural mesothelioma in vitro and in vivo
Cancer Letters 2023 October 10 [Link] Karin Schelch, Dominik Emminger, Benjamin Zitta, Thomas G Johnson, Verena Kopatz, Sebastian Eder, Alexander Ries, Alessia Stefanelli, Petra Heffeter, Mir A Hoda, Konrad Hoetzenecker, Balazs Dome, Walter Berger, Glen Reid, Michael Grusch Abstract Pleural mesothelioma (PM) is characterized by poor prognosis and limited therapeutic options. Y-box-binding protein 1 (YB-1)…
Read MoreHigh-dose IV magnesium in mesothelioma patients receiving surgery with hyperthermic intraoperative cisplatin: Pilot studies and design of a phase II randomized clinical trial
Journal of Surgical Oncology 2023 September 13 [Link] Shruti Gupta, Sophia L Wells, Arunima M Jose, Robert H Seitter, Lea Feghali, Nishant Devaraj, Philip M Hartigan, Stephanie Yacoubian, David J Kwiatkowski, Donna M Burke, Julianne Barlow, Raphael Bueno, David E Leaf Abstract Introduction: Hyperthermic intraoperative cisplatin (HIOC) is associated with acute kidney injury (AKI). Administration…
Read MoreInduction of metallothionein expression by supplementation of zinc induces resistance against platinum-based treatment in malignant pleural mesothelioma
Translational Cancer Research 2023 August 31 [Link] Martine Wyrich, Henning Ohlig, Michael Wessolly, Elena Mairinger, Julia Steinborn, Luka Brcic, Balazs Hegedus, Thomas Hager, Kristina Greimelmaier, Jeremias Wohlschlaeger, Fabian D Mairinger, Sabrina Borchert Abstract Background: Malignant pleural mesothelioma (MPM) is an aggressive tumor with a dismal prognosis. Currently, multimodality treatment including chemotherapy with cisplatin or carboplatin…
Read MoreCAMK2D: a novel molecular target for BAP1-deficient malignant mesothelioma
Cell Death Discovery 2023 July 21 [Link] Sivasundaram Karnan, Akinobu Ota, Hideki Murakami, Md Lutfur Rahman, Md Wahiduzzaman, Muhammad Nazmul Hasan, Lam Quang Vu, Ichiro Hanamura, Akihito Inoko, Miho Riku, Hideaki Ito, Yoshifumi Kaneko, Toshinori Hyodo, Hiroyuki Konishi, Shinobu Tsuzuki, Yoshitaka Hosokawa Abstract Malignant mesothelioma (MMe) is a rare but aggressive malignancy. Although the molecular…
Read More2022 PSOGI Consensus on HIPEC Regimens for Peritoneal Malignancies: Diffuse Malignant Peritoneal Mesothelioma
Annals of Surgical Oncology 2023 July 23 [Link] Vahan Kepenekian, Olivia Sgarbura, Frederic Marchal, Laurent Villeneuve, Shigeki Kusamura, Marcello Deraco Abstract Background: Diffuse malignant peritoneal mesothelioma (DMPM) is a rare and aggressive primary peritoneal disease, with recommended treatment, in eligible patients, of a combination of complete cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). As…
Read MoreCisplatin exhibits superiority over MMC as a perfusion agent in a peritoneal mesothelioma patient specific organoid HIPEC platform
Scientific Reports 2023 July 19 [Link] Steven D Forsythe, Richard A Erali, Nicholas Edenhoffer, William Meeker, Nadeem Wajih, Cecilia R Schaaf, Preston Laney, Cristian D Vanezuela, Wencheng Li, Edward A Levine, Shay Soker, Konstantinos I Votanopoulos Abstract Peritoneal mesothelioma (PM) is a rare malignancy with poor prognosis, representing about 10-15% of all mesothelioma cases. Herein…
Read MoreSETDB1 tumour suppressor roles in near-haploid mesothelioma involve TP53
British Journal of Cancer 2023 June 27 [Link] Mengting Xu, Yuqing Tu, Wenhui Bi, Meijun Z Lundberg, Isabella Klooster, Jonathan A Fletcher, Wen-Bin Ou Abstract Background: Mutational inactivation of the SETDB1 histone methyltransferase is found in a subset of mesothelioma, particularly in cases with near-haploidy and TP53 mutations. However, the tumourigenic consequences of SETDB1 inactivation…
Read MoreIndolyl-chalcone derivatives trigger apoptosis in cisplatin-resistant mesothelioma cells through aberrant tubulin polymerization and deregulation of microtubule-associated proteins
Frontiers in Oncology 2023 May 25 [Link] Sophia Steinlein, Frank Essmann, Amanda Franceschini Ghilardi, Heike Horn, Julia Schüler, Angelika Hausser, Lijun Sun, German Ott, Claudia Kalla Abstract Introduction: Malignant pleural mesothelioma (MPM) is a neoplasm with dismal prognosis and notorious resistance to the standard therapeutics cisplatin and pemetrexed. Chalcone derivatives are efficacious anti-cancer agents with…
Read MoreCytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma: Canadian practices and outcomes
Journal of Surgical Oncology 2023 May 30 [Link] Melina Deban, Kadhim Taqi, Gregory C Knapp, Mikael Soucisse, Matt Curry, Lucas Sidéris, Pierre Dubé, Maher Al Khaldi, Nicole Jedrzejko, Geoff Porter, Carman Giacomantonio, Trevor Hamilton, Andrea MacNeill, Lloyd Mack, Antoine Bouchard-Fortier Abstract Introduction: Peritoneal mesothelioma (PM) is a rare malignancy originating from the peritoneal lining. Cytoreductive…
Read MoreMatrigel-based organoid culture of malignant mesothelioma reproduces cisplatin sensitivity through CTR1
BMC Cancer 2023 May 31 [Link] Fumiya Ito, Katsuhiro Kato, Izumi Yanatori, Yuki Maeda, Toyoaki Murohara, Shinya Toyokuni Abstract Organoids are a three-dimensional (3D) culture system that simulate actual organs. Therefore, tumor organoids are expected to predict precise response to chemotherapy in patients. However, to date, few studies have studied the drug responses in organoids…
Read More